Signifor (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Signifor drug offered from Novartis Pharmaceuticals Corporation. This Somatostatin Analog [EPC],Somatostatin Receptor Agonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
NON-PROPRIETARY NAME: | pasireotide |
SUBSTANCE NAME: | PASIREOTIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Somatostatin Analog [EPC],Somatostatin Receptor Agonists [MoA] |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | INJECTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2012-12-14 |
END MARKETING DATE: | 0000-00-00 |
Signifor HUMAN PRESCRIPTION DRUG Details:
Item Description | Signifor from Novartis Pharmaceuticals Corporation |
LABELER NAME: | Novartis Pharmaceuticals Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.3(mg/mL) |
START MARKETING DATE: | 2012-12-14 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0078-0633_dd994d84-aaae-413e-9201-2ec5e7d1fcbd |
PRODUCT NDC: | 0078-0633 |
APPLICATION NUMBER: | NDA200677 |
Other PASIREOTIDE Pharmaceutical Manufacturers / Labelers: